KiteA Gilead Company
High-dose methylprednisolone(Kite, A Gilead Company)은 FRα 표적 치료제로, Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced 3M syndrome: a case report. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). 차별점: unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical.
FRα
Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma
Active
humanized anti-programmed death 1 (PD-1) monoclonal antibody, is widely used in the management of advanced ca
unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical
checkpoint inhibitor-induced 3M syndrome: a case report
immune-mediated necrotizing inflammatory myopathy
apoptosis of CD3/CD28-stimulated Jurkat cells, prioritizing this axis for future mechanistic testing without proving causality in
biomarkers and creatine kinase, alongside neuromuscular involvement, confirmed the clinical diagnosis of ICI-
downregulation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
KiteA Gilead Company
High-dose methylprednisolone(Kite, A Gilead Company)은 FRα 표적 치료제로, Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced 3M syndrome: a case report. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). 차별점: unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical.
FRα
Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma
Active
humanized anti-programmed death 1 (PD-1) monoclonal antibody, is widely used in the management of advanced ca
unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical
checkpoint inhibitor-induced 3M syndrome: a case report
immune-mediated necrotizing inflammatory myopathy
apoptosis of CD3/CD28-stimulated Jurkat cells, prioritizing this axis for future mechanistic testing without proving causality in
biomarkers and creatine kinase, alongside neuromuscular involvement, confirmed the clinical diagnosis of ICI-
downregulation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.